Mission Statement & Vision
- Currently existing companies have not optimally used the post-genomic information to seek novel biomarkers.
- A lot of errors are made in diagnosis of diseases, in prediction of the course of a disease. This results in delivering sub-optimal therapy.
- Problem: Diagnostic biomarkers studies are expensive, because of FDA approval.
- Best approach: To develop tools to biomarkers as research reagents but with ultimate intention of using as a diagnostic, in the clinical arena.